Compare ONL & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONL | CUE |
|---|---|---|
| Founded | 2021 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.4M | 177.0M |
| IPO Year | 2021 | 2017 |
| Metric | ONL | CUE |
|---|---|---|
| Price | $2.44 | $18.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $88.00 |
| AVG Volume (30 Days) | ★ 470.1K | 143.1K |
| Earning Date | 11-05-2026 | 11-16-2026 |
| Dividend Yield | ★ 3.23% | N/A |
| EPS Growth | N/A | ★ 61.11 |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $147,647,000.00 | $27,466,000.00 |
| Revenue This Year | $1.67 | N/A |
| Revenue Next Year | $0.11 | N/A |
| P/E Ratio | $13.05 | ★ N/A |
| Revenue Growth | N/A | ★ 195.75 |
| 52 Week Low | $1.89 | $0.17 |
| 52 Week High | $3.05 | $45.50 |
| Indicator | ONL | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 59.88 | 43.86 |
| Support Level | $2.40 | $18.20 |
| Resistance Level | $2.59 | $33.41 |
| Average True Range (ATR) | 0.12 | 1.86 |
| MACD | 0.05 | 0.49 |
| Stochastic Oscillator | 88.33 | 54.45 |
Orion Properties Inc is an internally managed real estate investment trust engaged in the ownership, acquisition, and management of a diversified portfolio of office properties located in high-quality suburban markets across the United States and leased mainly on a single-tenant net lease basis to creditworthy tenants. Its portfolio is comprised of traditional office properties, as well as governmental, medical office, flex/laboratory, and R&D and flex/industrial properties. The company is focused on shifting its portfolio concentration over time away from traditional office properties, towards more dedicated use assets with specialized uses that include an office component. It operates in one business segment: commercial real estate.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.